American Journal of Ophthalmology
Volume 149, Issue 4 , Pages 661-671.e1 , April 2010

Twelve-Month, Randomized, Controlled Trial of Bimatoprost 0.01%, 0.0125%, and 0.03% in Patients with Glaucoma or Ocular Hypertension

  • L. Jay Katz

      Affiliations

    • Wills Eye Hospital, Philadelphia, Pennsylvania
    • Corresponding Author InformationInquiries to L. Jay Katz, Glaucoma Service, Wills Eye Hospital, 840 Walnut Street, Suite 1110, Philadelphia, PA 19107
    • ,
  • John S. Cohen

      Affiliations

    • Cincinnati Eye Institute, Cincinnati, Ohio
    • ,
  • Amy L. Batoosingh

      Affiliations

    • Allergan, Inc, Irvine, California
    • ,
  • Carlos Felix

      Affiliations

    • Allergan, Inc, Irvine, California
    • ,
  • Vincent Shu

      Affiliations

    • Allergan, Inc, Irvine, California
    • ,
  • Rhett M. Schiffman

      Affiliations

    • Allergan, Inc, Irvine, California

,Accepted 1 December 2009.

References 

  1. Woodward DF, Phelps RL, Krauss AH, et al. Bimatoprost: a novel antiglaucoma agent. Cardiovasc Drug Rev. 2004;22:103–120
  2. Higginbotham EJ, Schuman JS, Goldberg I, et al. Bimatoprost Study Groups 1 and 2. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120:1286–1293
  3. Cohen JS, Gross RL, Cheetham JK, VanDenburgh AM, Bernstein P, Whitcup SM. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004;49(Suppl 1):S45–S52
  4. Williams RD, Cohen JS, Gross RL, Liu CC, Safyan E, Batoosingh AL Bimatoprost Study Group. Long-term efficacy and safety of bimatoprost for intraocular pressure lowering in glaucoma and ocular hypertension: year 4. Br J Ophthalmol. 2008;92:1387–1392
  5. Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J Glaucoma. 2008;17:667–673
  6. Noecker RS, Dirks MS, Choplin NT, Bernstein P, Batoosingh AL, Whitcup SM Bimatoprost/Latanoprost Study Group. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol. 2003;135:55–63
  7. Simmons ST, Dirks MS, Noecker RJ. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials. Adv Ther. 2004;21:247–262
  8. van der Valk R, Webers CA, Schouten JS, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177–1185
  9. Holmstrom S, Buchholz P, Walt J, Wickstrom J, Aagren M. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr Med Res Opin. 2005;21:1875–1883
  10. Cantor LB, Hoop J, Morgan L, Wudunn D, Catoira Y Bimatoprost-Travoprost Study Group. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension. Br J Ophthalmol. 2006;90:1370–1373
  11. Denis P, Lafuma A, Khoshnood B, Mimaud V, Berdeaux G. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr Med Res Opin. 2007;23:601–608
  12. Wanichwecha-Rungruang B, Iemsomboon W. Efficacy and safety of bimatoprost for the treatment of open-angle glaucoma and ocular hypertension: a three-month, open-label study in community-based practices in Thailand. J Med Assoc Thai. 2005;88:1228–1235
  13. Hommer A, Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17:53–62
  14. Holló G. The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 2007;6:45–52
  15. Nakamura T, Yamada M, Teshima M, et al. Electrophysiological characterization of tight junctional pathway of rabbit cornea treated with ophthalmic ingredients. Biol Pharm Bull. 2007;30:2360–2364
  16. Toor A, Chanis RA, Polikoff LA, Fahim MM, Sinha AP, Serle JB. Additivity of pilocarpine to bimatoprost in ocular hypertension and early glaucoma. J Glaucoma. 2005;14:243–248
  17. Le Henanff A, Giraudeau B, Baron G, Ravaud P. Quality of reporting of noninferiority and equivalence randomized trials. JAMA. 2006;295:1147–1151
  18. Schwartz GF, Reardon G. A cost-effectiveness comparison of bimatoprost versus latanoprost in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004;49:621–623author reply 623–624
  19. Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest Ophthalmol Vis Sci. 2004;45:1360–1368
  20. Guenoun JM, Baudouin C, Rat P, Pauly A, Warnet JM, Brignole-Baudouin F. In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:2444–2450
  21. Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther. 2006;23:663–671
  22. Liang H, Baudouin C, Pauly A, Brignole-Baudouin F. Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. Br J Ophthalmol. 2008;92:1275–1282
  23. Kahook MY, Noecker RJ. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears. Cornea. 2008;27:339–343
  24. Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter U, Ropo A. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf). 2008;242:14–19
  25. Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma. 2008;17:217–222
  26. Lewis RA, Katz GJ, Weiss MJ, et al. Travoprost BAC-free Study Group Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16:98–103
  27. Camras CB, Alm A, Watson P, Stjernschantz J Latanoprost Study Groups. Latanoprost, a prostaglandin analog, for glaucoma therapy (Efficacy and safety after 1 year of treatment in 198 patients). Ophthalmology. 1996;103:1916–1924
  28. Goldberg I, Li XY, Selaru P, Paggiarino D. A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2008;18:408–416
  29. Brandt JD, Beiser JA, Gordon MO, Kass MA Ocular Hypertension Treatment Study (OHTS) Group. Central corneal thickness and measured IOP response to topical ocular hypotensive medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2004;138:717–722
  30. Harasymowycz PJ, Papamatheakis DG, Ennis M, Brady M, Gordon KD Travoprost Central Corneal Thickness Study Group. Relationship between travoprost and central corneal thickness in ocular hypertension and open-angle glaucoma. Cornea. 2007;26:34–41

PII: S0002-9394(09)00906-4

doi: 10.1016/j.ajo.2009.12.003

American Journal of Ophthalmology
Volume 149, Issue 4 , Pages 661-671.e1 , April 2010

Article Tools

* Image Usage & Resolution